The Seraxis technologies provide a cure for insulin-dependent diabetes by replacing the lost insulin producing pancreatic cells with lab-grown cells, packaged within a device to protect the cells from immune rejection. This regenerative medicine strategy causes sustained reversal of diabetes in animal models. Seraxis scientific and medical experts have developed a stem cell line, SR1423 and differentiation protocol that reproducibly matures SR1423 cells to islets. These islets are organized like native islets containing cells secreting insulin and the other pancreatic hormones. The proprietary, clinically compliant (cGMP) stem cell line was generated from human pancreas.